Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyper-CVAD + maintenance chemotherapy
- Development stage
- Unknown
- Lead developer
- Peking University
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Hyper-CVAD + maintenance chemotherapy (Peking University protocol) is an intensive multi-agent chemotherapy regimen used for the treatment of adult patients with standard-risk acute lymphoblastic leukemia (ALL) in first complete remission (CR1). Developed and evaluated by researchers at Peking University, this protocol serves as a consolidation and maintenance strategy. The consolidation phase consists of alternating cycles of Hyper-CVAD-A (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and Hyper-CVAD-B (high-dose methotrexate and cytarabine). This is followed by a long-term maintenance phase comprising methotrexate, 6-mercaptopurine, and monthly pulses of vindesine and prednisone (VP). The regimen employs a diverse array of mechanisms, including DNA alkylation, inhibition of DNA and RNA synthesis, tubulin polymerization inhibition, and glucocorticoid-mediated apoptosis, to eradicate residual leukemic cells and prevent relapse.
- Other names
- Peking University ALL protocolHyper-CVAD consolidation and maintenance
02
Targets
DNAGR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DNA polymerase familyDHFR (Dihydrofolate reductase)PPAT (Amidophosphoribosyltransferase)
Beyond the preview
Go deeper on Hyper-CVAD + maintenance chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hyper-CVAD + maintenance chemotherapy.